Basit öğe kaydını göster

dc.contributor.authorÖZTÜRK, Nurinnisa
dc.contributor.authorIslek, Ali
dc.contributor.authorIlhan, Derya
dc.contributor.authorGÜVEN, BURCU
dc.contributor.authorSag, Elif
dc.date.accessioned2022-02-18T10:53:23Z
dc.date.available2022-02-18T10:53:23Z
dc.date.issued2021
dc.identifier.citationIslek A., Ilhan D., ÖZTÜRK N., GÜVEN B., Sag E., "Altered von Willebrand Factor and ADAMTS13 Levels in Children With Cirrhosis and Extrahepatic Portal Hypertension", JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, cilt.43, sa.7, 2021
dc.identifier.issn1077-4114
dc.identifier.otherav_c471cec8-6d7a-4452-9e67-af68020d016c
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/180104
dc.identifier.urihttps://doi.org/10.1097/mph.0000000000002038
dc.description.abstractBackground/Aim: This study was concerned with whether vWF (von Willebrand factor) and a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13 (ADAMTS13) has altered in patients with cirrhosis and extrahepatic portal hypertension (EPH). We aimed to investigate changes to vWF and ADAMTS13 in children with cirrhosis and EPH. Patients and Methods: This study was conducted between January and October 2019 with both cirrhosis and EPH patients and with healthy volunteers. The von Willebrand factor antigen (vWF:Ag), von Willebrand Ristocetin cofactor (vWF:RCo), and ADAMTS13 antigen and activity were studied. Results: Twenty-eight children with cirrhosis, 16 children with EPH, and 20 healthy controls were included in the study. vWF:Ag and vWF:RCo levels were higher in patients with cirrhosis than in healthy controls (171.65 +/- 101.67 vs. 85.86 +/- 30.58, P<0.01 and 121.62 +/- 55.83 vs. 61.52 +/- 27.03, P<0.01, respectively). vWF:Ag and vWF:RCo levels were higher in patients with EPH than in healthy controls (133.93 +/- 80.13 vs. 85.86 +/- 30.58, P<0.01 and 103.18 +/- 58.55 vs. 61.52 +/- 27.03, P=0.02, respectively). The ADAMTS13 antigen and activity levels were lower in patients with cirrhosis than in healthy controls (0.58 +/- 0.23 vs. 0.97 +/- 0.15, P<0.01 and 49.91 +/- 22.43 vs. 86.51 +/- 22.07, P=0.02, respectively). The ADAMTS13 antigen and activity levels were lower in patients with EPH than in healthy controls (0.69 +/- 0.11 vs. 0.97 +/- 0.15, P=0.03; and 68.50 +/- 13.29 vs. 86.51 +/- 22.07, P=0.02, respectively). The increase in vWF and the decrease in ADAMTS13 were more pronounced in cirrhotic patients with autoimmune hepatitis (AIH) than in non-AIH patients. Conclusions: While levels of vWF:Ag and vWF:RCo increased in children with cirrhosis and EPH, levels of the ADAMTS13 antigen and ADAMTS13 activity decreased. These alterations were more pronounced in patients with AIH-derived cirrhosis.
dc.language.isoeng
dc.subjectPediatrics
dc.subjectPediatrics, Perinatology and Child Health
dc.subjectHematology
dc.subjectHealth Sciences
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectHEMATOLOJİ
dc.subjectPEDİATRİ
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectÇocuk Sağlığı ve Hastalıkları
dc.subjectİç Hastalıkları
dc.subjectHematoloji
dc.subjectOnkoloji
dc.subjectOncology
dc.titleAltered von Willebrand Factor and ADAMTS13 Levels in Children With Cirrhosis and Extrahepatic Portal Hypertension
dc.typeMakale
dc.relation.journalJOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
dc.contributor.departmentAtatürk Üniversitesi , ,
dc.identifier.volume43
dc.identifier.issue7
dc.contributor.firstauthorID3060965


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster